Full Title
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, A Novel 2nd Generation PRMT5 Inhibitor, in Participants with MTAP-deleted Solid TumorsPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Ingo Mellinghoff’s office at 646-888-2766.
Protocol
26-192
Phase
Phase I (phase 1)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06914128
ClinicalTrials.gov